* K: Session in Korean
| Time | [ROOM 1AB] Grand Ballroom |
[ROOM 1C] Grand Ballroom |
[ROOM 2AB] Park Ballroom |
[ROOM 2C] Park Ballroom |
Time |
|---|
* K: Session in Korean
| Time | [ROOM 3] Studio123 |
[ROOM 4A] Studio4 |
[ROOM 4B] Studio5 |
[ROOM 4C] Studio6 |
[ROOM 4D] Studio7 |
Exhibition Hall |
Time |
|---|
| 07:30-08:00 |  KASL Branch EMW 2Daejeon-Sejong-Chungcheong (K)07:30-08:00 |
KASL Branch EMW 3 Daegu-Gyeongbuk (K) 07:30-08:00 |
KASL Branch EMW 4Gwangju -Chonnam (K) 07:30-08:10 |
Booth & Poster Exhibition 07:30-08:00 |
07:30-08:00 | ||
|---|---|---|---|---|---|---|---|
| 09:10-10:30 | KLTS Symposium 1LT for HCC with PVTT 09:10-10:30 |
Free Paper 1 09:10-10:30 |
Free Paper 2 09:10-10:30 |
Free Paper 3 09:10-10:30 |
Free Paper 4 09:10-10:30 |
09:10-10:30 | |
| 10:30-10:50 | Coffee Break 10:30-10:50 |
10:30-10:50 | |||||
| 11:40-12:40 | KLTS Coordinator Session (K) 11:40-12:40 |
11:40-12:40 | |||||
| 12:40-13:30 | Luncheon Symposium 7 12:40-13:30 |
Press onference Closed |
12:40-13:30 | ||||
| 13:30-14:50 | KLTS Symposium 2Body Composition and Fluid Dynamics in LT 13:30-14:50 |
Health Insurance, Policy Forum (K) 13:30-14:50 |
Free Paper 5 13:30-14:50 |
Free Paper 6 13:30-14:50 |
Free Paper 7 13:30-14:50 |
13:30-14:50 | |
| 14:50-16:10 | KLTS Symposium 3LT in the Era of MASLD 14:50-16:10 |
14:50-16:10 | |||||
| 16:20-17:20 | Poster Oral Presentation 16:20-17:20 |
16:20-17:20 | |||||
| 18:15-20:00 | Welcome Reception 18:15-20:00 |
18:15-20:00 | |||||
09:10-10:30
KASL Symposium 1
Redefining the Natural History of Chronic Hepatitis B: Expanding Treatment Paradigms
Chair: W. Ray Kim (Mayo Clinic, USA), Jaeyoun Cheong (Ajou Univ.)
- 09:10-09:30
-
Immunological Features of Chronic Hepatitis B: Stage-Independent Patterns of HBV-Specific T Cell Responses
Nina Le Bert (Duke-NUS Medical School, Singapore)
- 09:30-09:50
-
Clarifying the Indeterminate Phase in Chronic Hepatitis B: Defining Its Natural Course and Virological Characteristics
Gi-Ae Kim (Kyung Hee Univ.)
- 09:50-10:10
-
Impact of Antiviral Therapy in the Indeterminate Phase of Chronic Hepatitis B: Who Should Be Treated
Yao-Chun Hsu (I-Shou Univ., Taiwan)
- 10:10-10:30
-
Latest Updates on Novel Biomarkers for Chronic Hepatitis B
Yasuhito Tanaka (Kumamoto Univ., Japan)
11:10-11:40
President's Choice Lecture
Chair: Young-Suk Lim (Univ. of Ulsan)
- 11:10-11:40
-
From Clinic to Policy: A Physician's Journey toward Viral Hepatitis Eradication
Chien-Jen Chen (Genomics Research Center, Taiwan)
11:40-12:40
Plenary Presentation
Chair: Kyung Sik Kim (Yonsei Univ.), Yoon Jun Kim (Seoul National Univ.), Dong-Sik Kim (Korea Univ.)
13:30-14:50
KASL-AASLD Joint Symposium
Beyond Steatosis: Metabolic, Muscular, and Oncologic Implications of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Chair: Kathleen Corey (Harvard Medical School, USA), Young-Suk Lim (Univ. of Ulsan)
- 13:30-13:50
-
Public Health and Policy Implications in the Metabolic Era
Won Sohn (Sungkyunkwan Univ.)
- 13:50-14:10
-
Contemporary MASLD Management: Integrating Available Therapies, Metabolic Care, and Prevention of Sarcopenia
Hye Won Lee (Yonsei Univ.)
- 14:10-14:30
-
Near-Future MASLD Therapies: Resmetirom, GLP-1 Receptor Agonists and Emerging Agents
Kathleen Corey (Harvard Medical School, USA)
- 14:30-14:50
-
Rethinking HCC Surveillance in the MASLD Era: From Non-Cirrhotic Risk to Global Strategies
Ju Dong Yang (Cedars-Sinai Medical Center, USA)
14:50-16:10
KASL Symposium 3
From Cure to Care: Remaining Challenges in HBV Management
Chair: Jia-Horng Kao (National Taiwan Univ., Taiwan), Sang Hoon Ahn (Yonsei Univ.)
- 14:50-15:10
-
Expanding Indications for Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B: Clinical Benefits and Long-Term Outcomes
Dong Hyun Sinn (Sungkyunkwan Univ.)
- 15:10-15:30
-
Personalizing Antiviral Therapy in Hepatitis B: Balancing Safety, Efficacy, and HCC Prevention
Tung-Hung Su (National Taiwan Univ., Taiwan)
- 15:30-15:50
-
Discontinuation of Antiviral Therapy in Chronic Hepatitis B
Yao-Chun Hsu (I-Shou Univ., Taiwan)
- 15:50-16:10
-
Immune Mechanisms Driving HBsAg Decrease with Various Anti-HBV Therapeutics
Seng-Gee Lim (National Univ. of Singapore, Singapore)
16:20-17:40
KASL Symposium 4
Management Strategies for Chronic Viral Hepatitis
Chair: Man-Fung Yuen (The Univ. of Hong Kong, Hong Kong), Hyung Joon Yim (Korea Univ.)
- 16:20-16:40
-
Beyond Cure: Practical Care for Hepatitis C Patients with MASLD
Takumi Kawaguchi (Kurume Univ., Japan)
- 16:40-17:00
-
The Need for Greater Awareness and an Evolving Treatment Landscape in Hepatitis D Infection
Young Kul Jung (Korea Univ.)
- 17:00-17:20
-
Persistent Low-Level Viremia on Nucleos(t)ide Analogues in CHB Patients: Clinical Impact and Management Algorithms
Chun-Jen Liu (National Taiwan Univ., Taiwan)
- 17:20-17:40
-
AI-Driven Strategies for Chronic Hepatitis B: From Prediction to Post-Cure Risk Stratification
Moon Haeng Hur (Seoul National Univ.)
07:30-08:00
Mini Special Interest Group 1
The KASL Viral Hepatitis Study Group (*K)
Chair: Hyung Joon Yim (Korea Univ.)
- 07:30-08:00
-
Unmet Needs in the Clinical Practice of Viral Hepatitis
Janghan Jung (Hallym Univ.)
08:00-09:10
KASL-KAHBPS-KLCA-KLTS Joint Symposium
Expanding Horizons in Surgical Management of Hepatic Malignancies
Chair: Jung-Hwan Yoon (Seoul National Univ.), Deok-Bog Moon (Univ. of Ulsan)
- 08:00-08:15
-
Expanding Indications for Surgery and Transplantation in Hepatic Malignancies: Ethics, Donor Considerations, and Future Perspectives
Dong Hyun Sinn (Sungkyunkwan Univ.)
- 08:15-08:30
-
Downstaging and Conversion to Resection or Transplantation for Advanced HCC Using Systemic and Locoregional Therapies
Yun Bin Lee (Seoul National Univ.)
- 08:30-08:45
-
Surgical Management of Uncommon Hepatic Malignancies
Sang Jin Kim (Korea Univ.)
- 08:45-09:00
-
Liver Transplantation for Uncommon Hepatic Malignancies: Beyond Current Criteria
Sang-Hoon Kim (Univ. of Ulsan)
- 09:00-09:10
-
Discussion
13:30-14:50
KASL Symposium 2
Autoimmune Liver Diseases and Beyond
Chair: Tetsuo Takehara (Osaka Univ., Japan), Sook-Hyang Jeong (Seoul National Univ.)
- 13:30-13:50
-
Immunopathogenesis and Overlap Syndromes in Autoimmune Liver Diseases
Ja Kyung Kim (Yonsei Univ.)
- 13:50-14:10
-
Hard-to-Treat Autoimmune Liver Diseases: Lessons from Clinical Cases
Soon Kyu Lee (The Catholic Univ. of Korea)
- 14:10-14:30
-
Treatment Optimization in Autoimmune Hepatitis: When First-Line Therapy Fails
Atsumasa Komori (Nagasaki Univ., Japan)
- 14:30-14:50
-
Beyond Ursodeoxycholic Acid: The Next Chapter in Primary Biliary Cholangitis Treatment
Yu Jun Wong (Duke-NUS Medical School, Singapore)
14:50-16:10
Special Interest Group 1. KCSG & CHESS Joint Symposium
Leading the Frontiers of Cirrhotic Portal Hypertension in East Asia
Chairs: Won Hyeok Choe (Konkuk Univ.), Xiaolong Qi (Liver Health Consortium in China (CHESS), China)
- 14:50-15:10
-
Emerging Evidence: Ongoing Prospective Trials in Cirrhosis from Korea
Seong Hee Kang (Korea Univ.)
- 15:10-15:30
-
LiverRCT: CHESS Ongoing Randomized Controlled Trials of Cirrhotic Portal Hypertension
Xiaolong Qi (Liver Health Consortium in China (CHESS), China)
- 15:30-15:50
-
Clinical Insights from the Korean Multicenter HVPG Cohort
Tom Ryu (Soonchunhyang Univ.)
- 15:50-16:10
-
Vasomics: CHESS Emerging Technologies of Cirrhotic Portal Hypertension
Ling Yang (Southeast Univ., China)
16:20-17:40
Hepatology Associates (*K)
Chair: Il Han Song (Dankook Univ.), Hee Bok Chae (Chungbuk National Univ.)
- 16:20-16:40
-
Evaluation and Management of Abnormal Liver Function Tests in Clinical Practice
Byeong Geun Song (Sungkyunkwan Univ.)
- 16:40-17:00
-
Assessing Tumor Response in HCC: RECIST and mRECIST
Hyo Jung Park (Univ. of Ulsan)
- 17:00-17:20
-
Practical Approaches to Metabolic Dysfunction-Associated Steatohepatitis (MASH) Therapy and Complication Management
Ha Il Kim (Hanyang Univ.)
- 17:20-17:40
-
How to Report Complications: CTCAE and SUSAR
Taekeun Park (Seoul National Univ.)
09:10-10:30
KLCA Symposium 1
From Detection to Prevention: Evolving Strategies in Hepatocellular Carcinoma (HCC) Diagnosis and Chemoprevention
Chair: Yong-Han Paik (Sungkyunkwan Univ.), Seok Hyun Kim (Chungnam National Univ.)
- 09:10-09:30
-
Controversies in Imaging-Based Diagnosis of HCC: Revisiting Major Features and Regional Differences
Hyo Jung Park (Univ. of Ulsan)
- 09:30-09:50
-
AI-Driven Prediction and Risk Stratification for HCC Surveillance
Hyunjae Shin (Seoul National Univ.)
- 09:50-10:10
-
Biomarkers for HCC Diagnosis and Surveillance: Beyond AFP
Hye Won Lee (Yonsei Univ.)
- 10:10-10:30
-
Chemoprevention in MASLD: Can We Reduce the Risk of HCC?
Jeong Eun Song (Daegu Catholic Univ.)
13:40-14:40
2026 KLCA-NCC Practice Guidelines for Hepatocellular Carcinoma (*K)
Chair: June Sung Lee (Inje Univ.)
- 13:40-14:40
-
2026 KLCA-NCC Practice Guidelines for Hepatocellular Carcinoma
Bo Hyun Kim (National Cancer Center), Do Young Kim (Yonsei Univ.)
14:50-16:10
KLCA-ILCA Joint Symposium
Who Is the Best Partner for Anti-PD-1/PD-L1 in Advanced HCC: VEGF Inhibition vs. CTLA-4 Blockade
Chair: June Sung Lee (KLCA), Stephen Lam Chan (ILCA)
- 14:50-15:10
-
Evolving Landscape of Immunotherapy in HCC: Finding the Optimal Partner
Eui-Cheol Shin (KAIST)
- 15:10-15:30
-
Anti-VEGF as a Partner to PD-L1 Blockade
Antonio D'Alessio (King's College Hospital, UK)
- 15:30-15:50
-
Dual Immune Blockade in HCC
Bo Hyun Kim (National Cancer Center)
- 15:50-16:10
-
Panel Discussion: Choosing the Best Partner for Anti-PD-1/L1
16:20-17:40
KLCA Symposium 2
Managing MASLD-HCC: A Comprehensive Overview of Treatment Modalities and Strategies
Chair: Michael Karin (Sanford Burnham Prebys, USA), Antonio D'Alessio (King's College Hospital, UK)
- 16:20-16:40
-
MASLD-HCC Carcinogenesis: Genetics and Metabolic Drivers
Su Jong Yu (Seoul National Univ.)
- 16:40-17:00
-
Immunity and Resistance in MASLD-HCC: Strategies for Immune Checkpoint Inhibitor Therapy
Arndt Vogel (Univ. of Toronto, Canada)
- 17:00-17:20
-
Prognostic Imaging: Assessing Risk and Predicting Outcomes in MASLD-HCC
Sunyoung Lee (Yonsei Univ.)
- 17:20-17:40
-
Tailoring Immunotherapy for MASLD-HCC: Challenges and Emerging Strategies
Takahiro Kodama (Osaka Univ., Japan)
07:30-08:00
KASL Branch Early Morning Workshop 1 [Gyeonggi-Incheon] (*K)
Chair: Jung Hyun Kwon (The Catholic Univ. of Korea)
- 07:30-08:00
-
Clinical and Epidemiological Analysis of HEV Infection Based on the Nation-Wide Surveillance of Hepatitis E in Japan
Jong-Hon Kang (Teine Keijinkai Hospital, Japan)
08:00-09:00
Translational Research 1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pathogenesis and Metabolic-Immune Cross-Talk
Chair: Won Kim (Seoul National Univ.), Wonhyo Seo (Ewha Womans Univ.)
- 08:00-08:20
-
MASLD Phenotypic Diversity: From Genetic Discovery to Precision Medicine Stratification
Stefano Romeo (Karolinska Institutet, Sweden)
- 08:20-08:40
-
Inflammation-Fibrosis Axis and Regulatory Mechanisms in MASH
Yong-Hyun Han (Kangwon National Univ.)
- 08:40-09:00
-
The Metabolic Triad in MASLD-MASH: Glucose, Lipid, and Amino Acid Dysregulation
Tatsuya Kanto (Japan Institute for Health Security, Japan)
09:10-10:30
Translational Research 2
Cutting-Edge Technologies in Liver Research: From Spatial Omics to Precision Therapeutics
Chair: Si Hyun Bae (The Catholic Univ. of Korea), Won-Il Jeong (KAIST)
- 09:10-09:30
-
Hepatic Stellate Cell Activation and Fibrosis Reversal Mechanisms
David A. Brenner (Sanford Burnham Prebys, USA)
- 09:30-09:50
-
Multi-Omics and Single-Cell Spatial Insights for HCC Target Discovery
Jeong Seok Lee (KAIST)
- 09:50-10:10
-
Senescent Hepatocytes as Tumor Seedbeds in MASH: Lessons from Single-Cell Maps
Michael Karin (Sanford Burnham Prebys, USA)
- 10:10-10:30
-
Multi-Modal Analysis of Human Stellate Cells Identifies Novel Therapeutic Targets for MASLD
Hyun Young Kim (Dankook Univ.)
13:30-14:50
Data Science Camp 1 (*K)
Chairs: Hong Soo Kim (Soonchunhyang Univ.), Jeong Heo (Pusan National Univ.)
- 13:30-13:50
-
Principles of Cohort Study Design: From Question to Data
W. Ray Kim (Mayo Clinic, USA)
- 13:50-14:10
-
How to Conduct Successful Multinational Cohort Studies
Jeong-Hoon Lee (Seoul National Univ.)
- 14:10-14:30
-
From Statistical Associations to Causal Inference: The Role of Regression and Propensity Methods
Sehee Kim (Univ. of Ulsan)
- 14:30-14:50
-
Applying Survival and Multivariable Analysis in Clinical Research: Interpreting the Results
Dong Keon Yon (Kyung Hee Univ.)
14:50-16:10
Data Science Camp 2 (*K)
Chairs: Oh Sang Kwon (Gachon Univ.), Tae-Hee Lee (Konyang Univ.)
- 14:50-15:10
-
Target Trial Emulation in Hepatology Research
Kyunga Kim (Sungkyunkwan Univ.)
- 15:10-15:30
-
Application of Directed Acyclic Graphs (DAGs) and Mediation Analysis for Causal Inference
Sun Jae Jung (Yonsei Univ.)
- 15:30-15:50
-
Application of Vibe Coding in Liver Disease Research
Ji Won Han (The Catholic Univ. of Korea)
- 15:50-16:10
-
Sensitivity Analysis Methodologies in Epidemiologic Research
Hyesung Lee (Kangwon National Univ.)
16:20-17:20
Translational Hepatology
Integrative Approaches to Liver Diseases: Biomarkers, Microbiome, and Mendelian Randomization
Chairs: Jaeseok Hwang (Keimyung Univ.), Neung Hwa Park (Univ. of Ulsan)
- 16:20-16:40
-
Promotion of Precision Health Using Molecular and Genomic Biomarkers in Liver Diseases
Chien-Jen Chen (Genomics Research Center, Taiwan)
- 16:40-17:00
-
Microbiome-Metabolite Cross-Talk in Liver Diseases
Ki-Tae Suk (Hallym Univ.)
- 17:00-17:20
-
Genetic Causal Inference in Liver Diseases Using Mendelian Randomization
Sung Won Chung (Univ. of Ulsan)
09:10-10:30
KLTS Symposium 1
Liver Transplantation for HCC with Portal Vein Tumor Thrombosis: Redefining the Impossible
Chair: Young Kyoung You (The Catholic Univ. of Korea), Hae Won Lee (Seoul National Univ.)
- 09:10-09:30
-
Who, When, and Why: Selection Criteria and Timing for Liver Transplantation in HCC with Portal Vein Tumor Thrombosis
Jae Geun Lee (Yonsei Univ.)
- 09:30-09:50
-
Downstaging to Transplant: Converting the Unresectable to the Transplantable
Prashant Bhangui (Medanta Institute, India)
- 09:50-10:10
-
Operative Strategy and Technical Pitfalls in Liver Transplantation for HCC with Portal Vein Tumor Thrombosis
Deok-Bog Moon (Univ. of Ulsan)
- 10:10-10:30
-
Post-Transplant Care and Recurrence Management: Adjuvant and Salvage Strategies
Kwang-Woong Lee (Seoul National Univ.)
11:40-12:40
KLTS Coordinator Session (*K)
The Liver Transplant Patient Journey: Narratives and Experiences
Chair: Jung Ja Hong (Asan Medical Center), Seungheui Hong (Samsung Medical Center)
- 11:40-12:00
-
Analysis of Symptoms in Liver Transplant Recipients and Living Donors
JiYeon Choi (Yonsei Univ.)
- 12:00-12:20
-
Experience and Adaptation after Liver Transplantation: A Qualitative Research Review
Sunyoung Son (Gangnam Severance Hospital)
- 12:20-12:40
-
Depressive Symptoms and Self-Care in Liver Transplant Recipients
Seo Ha Jung (Yonsei Univ.)
13:30-14:50
KLTS Symposium 2
Body Composition and Fluid Dynamics in Liver Transplantation
Chair: Dong-Sik Kim (Korea Univ.), Bong-Wan Kim (Ajou Univ.)
- 13:30-13:50
-
Beyond Body Mass Index (BMI): Clinical Utility of InBody and Bioimpedance in Liver Transplant Evaluation
Suk-Won Suh (Chung-Ang Univ.)
- 13:50-14:10
-
Prognostic Significance of Sarcopenia and Visceral Fat in Liver Transplant Recipients
Toshimi Kaido (St. Luke's International Hospital, Japan)
- 14:10-14:30
-
Extracellular Water Imbalance and Fluid Overload: Impact on Early Graft Function and Complications
Minseob Kim (Seoul National Univ.)
- 14:30-14:50
-
Significance of Body Composition in Liver Transplantation
Seung-Young Oh (Seoul National Univ.)
14:50-16:10
KLTS Symposium 3
Liver Transplantation in the Era of MASLD
Chair: Kwang-Woong Lee (Seoul National Univ.), Prashant Bhangui (Medanta Institute, India)
- 14:50-15:10
-
The MASLD Era and Its Impact on the Liver Donor Pool
Bo Hyun Jung (Inje Univ.)
- 15:10-15:30
-
Outcomes and Risk Factors of Liver Transplantation Using Steatotic Grafts for HCC
Fengqiang Gao (Zhejiang Univ., China)
- 15:30-15:50
-
Recurrent Steatosis in Living Donors after Pre-Donation Weight Reduction and Subsequent Weight Regain
Young-in Yoon (Univ. of Ulsan)
- 15:50-16:10
-
Recurrent and de novo MASLD after Liver Transplantation
Tae-Seok Kim (Keimyung Univ.)
07:30-08:00
KASL Branch Early Morning Workshop 2 [Daejeon-Sejong-Chungcheong] (*K)
Chair: Seok Hyun Kim (Chungnam National Univ.)
- 07:30-08:00
-
Hepatorenal Syndrome in Patients with Hepatic Hydrothorax
Hyuk Soo Eun (Chungnam National Univ.)
13:30-14:45
Health Insurance, Policy Forum (*K)
Chair: In Hee Kim (Jeonbuk National Univ.), Hyun Woong Lee (Yonsei Univ.)
- 13:30-13:55
-
National Viral Hepatitis Elimination Strategy
TBD (Korea Disease Control and Prevention Agency)
- 13:55-14:20
-
Reimbursement Principles and History of Viral Hepatitis Treatment
Ae Ran Kwak (Health Insurance Review and Assessment Service)
- 14:20-14:45
-
Unmet Need of Clinical Practice in Chronic Viral Hepatitis
Soon Sun Kim (Ajou Univ.)
07:30-08:00
KASL Branch Early Morning Workshop 3 [Daegu-Gyeongbuk] (*K)
Chair: Won Young Tak (Kyungpook National Univ.)
- 07:30-08:00
-
Clinical Application of Non-Invasive Modalities for Fibrosis Assessment in MASLD
Byoung Kuk Jang (Keimyung Univ.)
07:30-08:00
KASL Branch Early Morning Workshop 4 [Gwangju -Chonnam] (*K)
Chair: Sung Bum Cho (Chonnam National Univ.)
- 07:30-08:00
-
Regionally Led Project for HCV Micro-Elimination: Jindo-gun
Min-Ho Shin (Chonnam National Univ.)
